Simulations Plus stock: First Eagle reports 4.4% holding

Published on 11/13/2026 at 01:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Simulations Plus stock is in focus after First Eagle disclosed a new beneficial-ownership filing. The report gives the investor sole control rights.

First Eagle Reports New Holding

First Eagle Investment Management reported sole voting and dispositive control over its Simulations Plus position.
The filing states that the shares were held in the ordinary course and not to influence corporate control.
Simulations Plus develops software for pharmacokinetic modeling, ADMET prediction, quantitative systems toxicology and quantitative systems pharmacology.

SLP, US8292141053, Illustration mit AI erstellt.

First Eagle Investment Management reported a beneficial interest in Simulations Plus on Tuesday, November 10, 2026, according to a StockTitan summary of the Schedule 13G/A. The filing identifies First Eagle Investment Management as the reporting investor and describes sole voting and dispositive power over the position.

Ownership Filing Sets Investor Focus

The report relates to the September 30, 2026 ownership date and was accepted by the U.S. Securities and Exchange Commission on November 10. It states that the shares were acquired and held in the ordinary course and were not held with the purpose or effect of changing or influencing control of the issuer.

For investors, the disclosure provides a fresh view of institutional ownership after a period marked by corporate changes at Simulations Plus. The filing itself does not announce an operating change, a new strategy or a transaction involving First Eagle.

Software Portfolio Targets Drug Development

Simulations Plus develops software for model-informed drug development and related pharmaceutical research. Its portfolio includes GastroPlus for absorption and pharmacokinetic modeling, ADMET Predictor for machine-learning-based property and toxicity prediction, DILIsym for quantitative systems toxicology and Thales for quantitative systems pharmacology, according to the company website.